Frédéric Triebel (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Frédéric Triebel" in English language version.

refsWebsite

Global rank English rank

12nih.gov

4^th place

8doi.org

2^nd place

4immutep.com

low place

2web.archive.org

1^st place

2primabiomed.com.au

low place

2semanticscholar.org

11^th place

8^th place

1aaihp.fr

low place

1free.fr

321^st place

724^th place

1legifrance.gouv.fr

265^th place

1,095^th place

1harvard.edu

18^th place

17^th place

1cnrs.fr

2,402^nd place

5,549^th place

aaihp.fr

"AAIHP - Les médailles d'or de l'AP-HP". www.aaihp.fr. Retrieved 20 November 2023.

cnrs.fr

"Archived copy" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 20 July 2015.{{cite web}}: CS1 maint: archived copy as title (link)

doi.org

Triebel, F; Jitsukawa, S; Baixeras, E; Roman-Roman, S; Genevee, C; Viegas-Pequignot, E; Hercend, T (1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–405. doi:10.1084/jem.171.5.1393. PMC 2187904. PMID 1692078.
Baixeras, E; Huard, B; Miossec, C; Jitsukawa, S; Martin, M; Hercend, T; Auffray, C; Triebel, F; Piatier-Tonneau, D (1992). "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327–37. doi:10.1084/jem.176.2.327. PMC 2119326. PMID 1380059.
Huard, B; Mastrangeli, R; Prigent, P; Bruniquel, D; Donini, S; El-Tayar, N; Maigret, B; Dréano, M; Triebel, F (1997). "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5744–9. Bibcode:1997PNAS...94.5744H. doi:10.1073/pnas.94.11.5744. PMC 20850. PMID 9159144.
Bruniquel, D; Borie, N; Hannier, S; Triebel, F (1998). "Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II". Immunogenetics. 48 (2): 116–24. doi:10.1007/s002510050411. PMID 9634475. S2CID 24657573.
Hannier, S; Tournier, M; Bismuth, G; Triebel, F (1998). "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling". Journal of Immunology. 161 (8): 4058–65. doi:10.4049/jimmunol.161.8.4058. PMID 9780176. S2CID 21850137.
Triebel, F (2003). "LAG-3: A regulator of T-cell and DC responses and its use in therapeutic vaccination". Trends in Immunology. 24 (12): 619–22. doi:10.1016/j.it.2003.10.001. PMID 14644131.
Brignone C; Escudier B; Grygar C; Marcu M; Triebel F. (1 October 2009). "A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma". Clinical Cancer Research. 15 (19): 6225–31. doi:10.1158/1078-0432.CCR-09-0068. PMID 19755389.
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, Marcu M, Triebel F (23 July 2010). "First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity". J Transl Med. 8 (71): 71. doi:10.1186/1479-5876-8-71. PMC 2920252. PMID 20653948.

free.fr

immunology.free.fr

"Professor Frédéric TRIEBEL". Immunology.free.fr. Retrieved 30 April 2015.

harvard.edu

ui.adsabs.harvard.edu

Huard, B; Mastrangeli, R; Prigent, P; Bruniquel, D; Donini, S; El-Tayar, N; Maigret, B; Dréano, M; Triebel, F (1997). "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5744–9. Bibcode:1997PNAS...94.5744H. doi:10.1073/pnas.94.11.5744. PMC 20850. PMID 9159144.

immutep.com

"Frédéric Triebel, MD Ph.D." www.immutep.com. Retrieved 9 December 2019.
"LAG-3 – Regulating the Immune System | Immutep". www.immutep.com. Retrieved 9 December 2019.
"Immutep Closes Funding to develop Novel Therapeutic Vaccines" (PDF). Immutep.com. Retrieved 30 April 2015. ^{[permanent dead link]}
"Immutep Closes Second Funding to Enter Clinic" (PDF). Immutep.com. Retrieved 30 April 2015. ^{[permanent dead link]}

legifrance.gouv.fr

"Arrêté du 5 juillet 1993 portant nomination à l'Institut universitaire de France - Légifrance". Retrieved 20 November 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Triebel, F; Jitsukawa, S; Baixeras, E; Roman-Roman, S; Genevee, C; Viegas-Pequignot, E; Hercend, T (1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–405. doi:10.1084/jem.171.5.1393. PMC 2187904. PMID 1692078.
Baixeras, E; Huard, B; Miossec, C; Jitsukawa, S; Martin, M; Hercend, T; Auffray, C; Triebel, F; Piatier-Tonneau, D (1992). "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327–37. doi:10.1084/jem.176.2.327. PMC 2119326. PMID 1380059.
Huard, B; Mastrangeli, R; Prigent, P; Bruniquel, D; Donini, S; El-Tayar, N; Maigret, B; Dréano, M; Triebel, F (1997). "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5744–9. Bibcode:1997PNAS...94.5744H. doi:10.1073/pnas.94.11.5744. PMC 20850. PMID 9159144.
Bruniquel, D; Borie, N; Hannier, S; Triebel, F (1998). "Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II". Immunogenetics. 48 (2): 116–24. doi:10.1007/s002510050411. PMID 9634475. S2CID 24657573.
Hannier, S; Tournier, M; Bismuth, G; Triebel, F (1998). "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling". Journal of Immunology. 161 (8): 4058–65. doi:10.4049/jimmunol.161.8.4058. PMID 9780176. S2CID 21850137.
Triebel, F (2003). "LAG-3: A regulator of T-cell and DC responses and its use in therapeutic vaccination". Trends in Immunology. 24 (12): 619–22. doi:10.1016/j.it.2003.10.001. PMID 14644131.
Brignone C; Escudier B; Grygar C; Marcu M; Triebel F. (1 October 2009). "A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma". Clinical Cancer Research. 15 (19): 6225–31. doi:10.1158/1078-0432.CCR-09-0068. PMID 19755389.
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, Marcu M, Triebel F (23 July 2010). "First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity". J Transl Med. 8 (71): 71. doi:10.1186/1479-5876-8-71. PMC 2920252. PMID 20653948.

ncbi.nlm.nih.gov

Triebel, F; Jitsukawa, S; Baixeras, E; Roman-Roman, S; Genevee, C; Viegas-Pequignot, E; Hercend, T (1990). "LAG-3, a novel lymphocyte activation gene closely related to CD4". The Journal of Experimental Medicine. 171 (5): 1393–405. doi:10.1084/jem.171.5.1393. PMC 2187904. PMID 1692078.
Baixeras, E; Huard, B; Miossec, C; Jitsukawa, S; Martin, M; Hercend, T; Auffray, C; Triebel, F; Piatier-Tonneau, D (1992). "Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens". The Journal of Experimental Medicine. 176 (2): 327–37. doi:10.1084/jem.176.2.327. PMC 2119326. PMID 1380059.
Huard, B; Mastrangeli, R; Prigent, P; Bruniquel, D; Donini, S; El-Tayar, N; Maigret, B; Dréano, M; Triebel, F (1997). "Characterization of the major histocompatibility complex class II binding site on LAG-3 protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (11): 5744–9. Bibcode:1997PNAS...94.5744H. doi:10.1073/pnas.94.11.5744. PMC 20850. PMID 9159144.
Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, Bousetta N, Medioni J, Gligorov J, Grygar C, Marcu M, Triebel F (23 July 2010). "First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity". J Transl Med. 8 (71): 71. doi:10.1186/1479-5876-8-71. PMC 2920252. PMID 20653948.

primabiomed.com.au

"Prima Announces Immutep's IMP321 Patent Application Receives Australian Notice of Allowance" (PDF). Primabiomed.com.au. Archived from the original (PDF) on 20 March 2016. Retrieved 30 April 2015.
"Prima Biomed". Primabiomed.com.au. 17 December 2014. Retrieved 30 April 2015.

semanticscholar.org

api.semanticscholar.org

Bruniquel, D; Borie, N; Hannier, S; Triebel, F (1998). "Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II". Immunogenetics. 48 (2): 116–24. doi:10.1007/s002510050411. PMID 9634475. S2CID 24657573.
Hannier, S; Tournier, M; Bismuth, G; Triebel, F (1998). "CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling". Journal of Immunology. 161 (8): 4058–65. doi:10.4049/jimmunol.161.8.4058. PMID 9780176. S2CID 21850137.

web.archive.org

"Prima Announces Immutep's IMP321 Patent Application Receives Australian Notice of Allowance" (PDF). Primabiomed.com.au. Archived from the original (PDF) on 20 March 2016. Retrieved 30 April 2015.
"Archived copy" (PDF). Archived from the original (PDF) on 3 March 2016. Retrieved 20 July 2015.{{cite web}}: CS1 maint: archived copy as title (link)